Loading...
Please wait, while we are loading the content...
Similar Documents
Ado-Trastuzumab Emtansine – The Monoclonal Drug Conjugate in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
| Content Provider | Scilit |
|---|---|
| Author | Ganguly, Sandip Ghosh, Joydeep Biswas, Bivas Dabkara, Deepak |
| Copyright Year | 2020 |
| Description | Human epidermal growth factor receptor 2 (HER2)-positive breast cancer comprises around 20%–25% of breast cancers. With the discovery of trastuzumab, there was a marked improvement in the survival of patients with HER2-positive breast cancer both in curative and metastatic settings. However, patients with trastuzumab will eventually progress or develop recurrences. Newer anti-HER2 therapies have evolved to improve the outcome of this group of patients. One of them is monoclonal antibody–drug conjugate which is ado-trastuzumab emtansine. |
| Related Links | http://www.ijmpo.org/article.asp?issn=0971-5851;year=2020;volume=41;issue=2;spage=218;epage=220;aulast=Ganguly;type=2 |
| Ending Page | 220 |
| Page Count | 3 |
| Starting Page | 218 |
| ISSN | 09715851 |
| e-ISSN | 09752129 |
| DOI | 10.4103/ijmpo.ijmpo_246_19 |
| Journal | Indian Journal of Medical and Paediatric Oncology |
| Issue Number | 02 |
| Volume Number | 41 |
| Language | English |
| Publisher | Georg Thieme Verlag KG |
| Publisher Date | 2020-03-01 |
| Access Restriction | Open |
| Subject Keyword | Journal: Indian Journal of Medical and Paediatric Oncology Breast Cancer Human Epidermal Growth Factor Receptor 2 Positive Trastuzumab Emtansine |
| Content Type | Text |
| Resource Type | Article |
| Subject | Pediatrics, Perinatology and Child Health Oncology |
